vs
Side-by-side financial comparison of Orange County Bancorp, Inc. (OBT) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Orange County Bancorp, Inc. is the larger business by last-quarter revenue ($33.0M vs $20.6M, roughly 1.6× Entrada Therapeutics, Inc.). Orange County Bancorp, Inc. runs the higher net margin — 37.6% vs -84.4%, a 122.0% gap on every dollar of revenue. On growth, Orange County Bancorp, Inc. posted the faster year-over-year revenue change (20.6% vs -65.2%). Orange County Bancorp, Inc. produced more free cash flow last quarter ($41.3M vs $-39.7M). Over the past eight quarters, Orange County Bancorp, Inc.'s revenue compounded faster (14.3% CAGR vs 6.4%).
Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
OBT vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $33.0M | $20.6M |
| Net Profit | $12.4M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | 41.4% | -106.0% |
| Net Margin | 37.6% | -84.4% |
| Revenue YoY | 20.6% | -65.2% |
| Net Profit YoY | 73.5% | -173.8% |
| EPS (diluted) | $0.94 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $33.0M | — | ||
| Q3 25 | $33.7M | — | ||
| Q2 25 | $32.5M | — | ||
| Q1 25 | $28.0M | $20.6M | ||
| Q4 24 | $27.4M | $37.4M | ||
| Q3 24 | $27.1M | $19.6M | ||
| Q2 24 | $27.9M | $94.7M | ||
| Q1 24 | $25.3M | $59.1M |
| Q4 25 | $12.4M | — | ||
| Q3 25 | $10.0M | — | ||
| Q2 25 | $10.5M | — | ||
| Q1 25 | $8.7M | $-17.3M | ||
| Q4 24 | $7.2M | $1.1M | ||
| Q3 24 | $3.2M | $-14.0M | ||
| Q2 24 | $8.2M | $55.0M | ||
| Q1 24 | $9.3M | $23.5M |
| Q4 25 | 41.4% | — | ||
| Q3 25 | 38.6% | — | ||
| Q2 25 | 41.9% | — | ||
| Q1 25 | 40.3% | -106.0% | ||
| Q4 24 | 32.8% | -15.7% | ||
| Q3 24 | 14.8% | -110.7% | ||
| Q2 24 | 36.6% | 56.4% | ||
| Q1 24 | 45.9% | 35.7% |
| Q4 25 | 37.6% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 32.2% | — | ||
| Q1 25 | 31.1% | -84.4% | ||
| Q4 24 | 26.2% | 3.0% | ||
| Q3 24 | 11.8% | -71.7% | ||
| Q2 24 | 29.4% | 58.1% | ||
| Q1 24 | 36.7% | 39.7% |
| Q4 25 | $0.94 | — | ||
| Q3 25 | $0.75 | — | ||
| Q2 25 | $0.87 | — | ||
| Q1 25 | $0.77 | $-0.42 | ||
| Q4 24 | $0.64 | $-0.20 | ||
| Q3 24 | $0.28 | $-0.35 | ||
| Q2 24 | $0.73 | $1.55 | ||
| Q1 24 | $0.82 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $284.4M | $417.3M |
| Total Assets | $2.7B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $67.8M | ||
| Q4 24 | — | $101.2M | ||
| Q3 24 | — | $78.0M | ||
| Q2 24 | — | $185.3M | ||
| Q1 24 | — | $68.4M |
| Q4 25 | $284.4M | — | ||
| Q3 25 | $270.1M | — | ||
| Q2 25 | $252.6M | — | ||
| Q1 25 | $201.3M | $417.3M | ||
| Q4 24 | $185.5M | $428.7M | ||
| Q3 24 | $193.1M | $422.4M | ||
| Q2 24 | $177.5M | $429.9M | ||
| Q1 24 | $168.7M | $269.4M |
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | $486.5M | ||
| Q4 24 | $2.5B | $526.3M | ||
| Q3 24 | $2.5B | $554.6M | ||
| Q2 24 | $2.5B | $582.0M | ||
| Q1 24 | $2.5B | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.8M | $-38.5M |
| Free Cash FlowOCF − Capex | $41.3M | $-39.7M |
| FCF MarginFCF / Revenue | 125.1% | -192.9% |
| Capex IntensityCapex / Revenue | 7.6% | 5.6% |
| Cash ConversionOCF / Net Profit | 3.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $69.6M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.8M | — | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $-5.0M | — | ||
| Q1 25 | $4.8M | $-38.5M | ||
| Q4 24 | $34.6M | $-31.6M | ||
| Q3 24 | $10.2M | $-24.3M | ||
| Q2 24 | $9.3M | $39.8M | ||
| Q1 24 | $2.3M | $-25.5M |
| Q4 25 | $41.3M | — | ||
| Q3 25 | $29.6M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $4.3M | $-39.7M | ||
| Q4 24 | $32.9M | $-32.2M | ||
| Q3 24 | $10.0M | $-24.9M | ||
| Q2 24 | $9.2M | $38.8M | ||
| Q1 24 | $2.0M | $-26.4M |
| Q4 25 | 125.1% | — | ||
| Q3 25 | 87.8% | — | ||
| Q2 25 | -17.5% | — | ||
| Q1 25 | 15.5% | -192.9% | ||
| Q4 24 | 120.0% | -86.2% | ||
| Q3 24 | 36.7% | -127.3% | ||
| Q2 24 | 32.8% | 41.0% | ||
| Q1 24 | 7.9% | -44.6% |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 1.8% | 5.6% | ||
| Q4 24 | 6.3% | 1.7% | ||
| Q3 24 | 1.1% | 3.3% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 1.0% | 1.4% |
| Q4 25 | 3.53× | — | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | -0.47× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 4.83× | -27.94× | ||
| Q3 24 | 3.19× | — | ||
| Q2 24 | 1.13× | 0.72× | ||
| Q1 24 | 0.24× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
